6.70
price up icon0.45%   0.03
after-market Dopo l'orario di chiusura: 6.70
loading
Precedente Chiudi:
$6.67
Aprire:
$6.64
Volume 24 ore:
717.29K
Relative Volume:
0.37
Capitalizzazione di mercato:
$987.43M
Reddito:
$62.04M
Utile/perdita netta:
$-533.34M
Rapporto P/E:
-1.7092
EPS:
-3.92
Flusso di cassa netto:
$-473.07M
1 W Prestazione:
-3.32%
1M Prestazione:
-17.39%
6M Prestazione:
-11.02%
1 anno Prestazione:
-33.86%
Intervallo 1D:
Value
$6.515
$6.71
Intervallo di 1 settimana:
Value
$6.40
$7.22
Portata 52W:
Value
$6.40
$14.45

Vir Biotechnology Inc Stock (VIR) Company Profile

Name
Nome
Vir Biotechnology Inc
Name
Telefono
415-906-4324
Name
Indirizzo
1800 OWENS STREET, SAN FRANCISCO, CA
Name
Dipendente
0
Name
Cinguettio
@Vir_Biotech
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
VIR's Discussions on Twitter

Confronta VIR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VIR
Vir Biotechnology Inc
6.70 987.43M 62.04M -533.34M -473.07M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-01-29 Downgrade JP Morgan Overweight → Neutral
2023-09-08 Downgrade BofA Securities Buy → Neutral
2023-03-06 Aggiornamento JP Morgan Neutral → Overweight
2023-02-21 Aggiornamento Goldman Neutral → Buy
2023-01-27 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2022-09-14 Iniziato SVB Leerink Outperform
2022-09-09 Iniziato Morgan Stanley Underweight
2022-03-03 Aggiornamento Robert W. Baird Underperform → Neutral
2021-12-21 Downgrade Robert W. Baird Neutral → Underperform
2021-10-25 Aggiornamento JP Morgan Underweight → Neutral
2021-09-22 Downgrade Goldman Buy → Neutral
2021-06-04 Ripresa Robert W. Baird Neutral
2021-01-27 Downgrade JP Morgan Neutral → Underweight
2021-01-20 Reiterato H.C. Wainwright Buy
2020-10-05 Iniziato BofA Securities Buy
2020-09-14 Aggiornamento Goldman Neutral → Buy
2020-09-11 Aggiornamento JP Morgan Underweight → Neutral
2020-08-20 Iniziato Needham Buy
2020-03-19 Downgrade JP Morgan Neutral → Underweight
2020-03-13 Downgrade Goldman Buy → Neutral
2020-02-27 Downgrade Robert W. Baird Neutral → Underperform
2020-02-04 Downgrade JP Morgan Overweight → Neutral
2019-11-14 Iniziato Robert W. Baird Neutral
2019-11-05 Iniziato Barclays Overweight
2019-11-05 Iniziato Cowen Outperform
2019-11-05 Iniziato Goldman Buy
2019-11-05 Iniziato JP Morgan Overweight
Mostra tutto

Vir Biotechnology Inc Borsa (VIR) Ultime notizie

pulisher
Mar 28, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company - Yahoo Finance

Mar 28, 2025
pulisher
Mar 26, 2025

Vir Biotechnology stock hits 52-week low at $6.54 By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Vir Biotechnology stock hits 52-week low at $6.54 - Investing.com India

Mar 26, 2025
pulisher
Mar 24, 2025

(VIR) Trading Advice - Stock Traders Daily

Mar 24, 2025
pulisher
Mar 21, 2025

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - Quantisnow

Mar 21, 2025
pulisher
Mar 13, 2025

(VIR) Trading Signals - Stock Traders Daily

Mar 13, 2025
pulisher
Mar 13, 2025

Morgan Stanley maintains $20 target on Vir Biotechnology stock By Investing.com - Investing.com Canada

Mar 13, 2025
pulisher
Mar 13, 2025

Morgan Stanley maintains $20 target on Vir Biotechnology stock - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Vir Biotechnology Enrolls First Patient in Phase 3 Chronic Hepatitis Delta Trial -March 13, 2025 at 08:30 am EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire

Mar 13, 2025
pulisher
Mar 11, 2025

Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus.com

Mar 11, 2025
pulisher
Mar 11, 2025

SBI Securities Co. Ltd. Invests $60,000 in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

Brokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $35.67 - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

Vir Biotechnology price target raised to $14 from $10 at JPMorgan - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Principal Financial Group Inc. Has $3.28 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Rhumbline Advisers Has $1.74 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology (NASDAQ:VIR) - Seeking Alpha

Mar 04, 2025
pulisher
Mar 03, 2025

Vir Biotechnology's (VIR) Buy Rating Reiterated at Needham & Company LLC - MarketBeat

Mar 03, 2025
pulisher
Mar 03, 2025

What is HC Wainwright’s Forecast for VIR Q1 Earnings? - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

(VIR) On The My Stocks Page - Stock Traders Daily

Mar 02, 2025
pulisher
Mar 02, 2025

HC Wainwright Reaffirms “Buy” Rating for Vir Biotechnology (NASDAQ:VIR) - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

Vir Biotechnology’s Strategic Advancements and Financial Health Justify Buy Rating - TipRanks

Mar 02, 2025
pulisher
Mar 02, 2025

Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, Barclays Analyst Says - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Canada Finance

Mar 01, 2025
pulisher
Feb 28, 2025

7 Analysts Have This To Say About Vir Biotechnology - Benzinga

Feb 28, 2025
pulisher
Feb 28, 2025

Decoding Vir Biotechnology Inc (VIR): A Strategic SWOT Insight - GuruFocus.com

Feb 28, 2025
pulisher
Feb 27, 2025

Vir Biotechnology’s Transformative Year: Earnings Call Insights - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology Becomes Oversold (VIR) - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock By Investing.com - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock - Investing.com India

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025
pulisher
Feb 27, 2025

Promising Oncology Developments and Strong Financial Outlook Support Buy Rating for Vir Biotechnology - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology’s Promising Pipeline and Strong Financial Position Justify Buy Rating - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology: Balancing Long-term Potential with Near-term Uncertainty – A Hold Rating Analysis - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Hansoh ends collaboration with Silence; Vir hunts for HBV drug partner - Endpoints News

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - BioSpace

Feb 27, 2025
pulisher
Feb 26, 2025

Vir Biotechnology Reports 2024 Financial Results and Strategic Advances - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Vir Biotechnology: Strong Financial Position and Promising Pipeline Justify Buy Rating - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Earnings call transcript: Vir Biotech beats Q4 2024 forecasts, stock rises - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

Vir Biotechnology Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 26, 2025
pulisher
Feb 26, 2025

Vir Biotechnology reports Q4 EPS (76c), consensus (87c) - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 11c - StreetInsider.com

Feb 26, 2025
pulisher
Feb 25, 2025

Vir Biotechnology CEO sells $152,407 in stock By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Vir Biotechnology's SVP sells shares worth $14,766 By Investing.com - Investing.com Canada

Feb 25, 2025
pulisher
Feb 25, 2025

Vir Biotechnology EVP vanina de Verneuil sells $48,590 in shares By Investing.com - Investing.com Australia

Feb 25, 2025

Vir Biotechnology Inc Azioni (VIR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
Capitalizzazione:     |  Volume (24 ore):